Share-based Payment Arrangement, Expense of Perspective Therapeutics, Inc. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Perspective Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • Perspective Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,156,000, a 10% increase year-over-year.
  • Perspective Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,717,000, a 126% increase year-over-year.
  • Perspective Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,221,000, a 66% increase from 2023.
  • Perspective Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,143,000, a 306% increase from 2022.
  • Perspective Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $775,000, a 101% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Perspective Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,717,000 $2,156,000 +$204,000 +10% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $8,513,000 $2,403,000 +$1,816,000 +309% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $6,697,000 $2,098,000 +$1,476,000 +237% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $5,221,000 $2,060,000 +$1,367,000 +197% 01 Oct 2024 31 Dec 2024 10-K/A 28 Mar 2025 2024 FY
Q3 2024 $3,854,000 $1,952,000 +$1,534,000 +367% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $2,320,000 $587,000 -$463,000 -44% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $2,783,000 $622,000 -$360,000 -37% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $3,143,000 $693,000 01 Oct 2023 31 Dec 2023 10-K/A 28 Mar 2025 2024 FY
Q3 2023 $418,000 -$47,000 -10% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $1,050,000 +$896,000 +582% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $982,000 +$825,000 +525% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q3 2022 $956,000 $465,000 -$131,000 -22% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $1,087,000 $154,000 +$28,000 +22% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $1,059,000 $157,000 +$63,000 +67% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $996,000 $180,000 +$99,000 +122% 01 Oct 2021 31 Dec 2021 10-Q 09 Feb 2022 2022 Q2
Q3 2021 $897,000 $596,000 +$511,000 +601% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2023 Q1
Q2 2021 $386,000 $126,000 -$93,000 -42% 01 Apr 2021 30 Jun 2021 10-KT 01 May 2023 2023 Q1
Q1 2021 $479,000 $94,000 +$3,000 +3.3% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q3
Q4 2020 $476,000 $81,000 -$13,000 -14% 01 Oct 2020 31 Dec 2020 10-Q 09 Feb 2022 2022 Q2
Q3 2020 $489,000 $85,000 -$6,000 -6.6% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2022 Q1
Q2 2020 $495,000 $219,000 +$68,000 +45% 01 Apr 2020 30 Jun 2020 10-KT 01 May 2023 2023 Q1
Q1 2020 $427,000 $91,000 +$12,000 +15% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q3
Q4 2019 $415,000 $94,000 -$3,000 -3.1% 01 Oct 2019 31 Dec 2019 10-Q 09 Feb 2021 2021 Q2
Q3 2019 $418,000 $91,000 -$2,000 -2.2% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2021 Q1
Q2 2019 $420,000 $151,000 -$8,000 -5% 01 Apr 2019 30 Jun 2019 10-K 27 Sep 2021 2021 FY
Q1 2019 $428,000 $79,000 +$2,000 +2.6% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q3
Q4 2018 $426,000 $97,000 +$19,000 +24% 01 Oct 2018 31 Dec 2018 10-Q 12 Feb 2020 2020 Q2
Q3 2018 $407,000 $93,000 +$3,000 +3.3% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2020 Q1
Q2 2018 $404,000 $159,000 -$51,000 -24% 01 Apr 2018 30 Jun 2018 10-K 25 Sep 2020 2020 FY
Q1 2018 $455,000 $77,000 +$37,000 +92% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q3
Q4 2017 $418,000 $78,000 +$26,000 +50% 01 Oct 2017 31 Dec 2017 10-Q 13 Feb 2019 2019 Q2
Q3 2017 $392,000 $90,000 +$20,000 +29% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2019 Q1
Q2 2017 $372,000 $210,000 +$149,000 +244% 01 Apr 2017 30 Jun 2017 10-K 27 Sep 2019 2019 FY
Q1 2017 $223,000 $40,000 -$126,000 -76% 01 Jan 2017 31 Mar 2017 10-Q 04 May 2018 2018 Q3
Q4 2016 $349,000 $52,000 +$21,000 +68% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018 2018 Q2
Q3 2016 $328,000 $70,000 +$38,000 +119% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017 2018 Q1
Q2 2016 $290,000 $61,000 -$79,642 -57% 01 Apr 2016 30 Jun 2016 10-K 26 Sep 2018 2018 FY
Q1 2016 $369,642 $166,000 +$144,548 +674% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q3
Q4 2015 $225,094 $31,000 +$9,547 +45% 01 Oct 2015 31 Dec 2015 10-Q 09 Feb 2017 2017 Q2
Q3 2015 $215,547 $32,000 +$10,547 +49% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2017 Q1
Q2 2015 $205,000 $140,642 +$19,873 +16% 01 Apr 2015 30 Jun 2015 10-K 28 Sep 2017 2017 FY
Q1 2015 $185,127 $21,452 +$8,019 +60% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q3
Q4 2014 $177,108 $21,453 +$8,021 +60% 01 Oct 2014 31 Dec 2014 10-Q 09 Feb 2016 2016 Q2
Q3 2014 $169,087 $21,453 -$16,900 -44% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2016 Q1
Q2 2014 $185,987 $120,769 +$97,787 +425% 01 Apr 2014 30 Jun 2014 10-K 09 Sep 2016 2016 FY
Q1 2014 $88,200 $13,433 -$14,147 -51% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015 2015 Q3
Q4 2013 $102,347 $13,432 -$15,394 -53% 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015 2015 Q2
Q3 2013 $117,741 $38,353 +$9,390 +32% 01 Jul 2013 30 Sep 2013 10-Q 14 Nov 2014 2015 Q1
Q2 2013 $108,351 $22,982 01 Apr 2013 30 Jun 2013 10-K 14 Sep 2015 2015 FY
Q1 2013 $27,580 -$5,610 -17% 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014 2014 Q3
Q4 2012 $28,826 -$4,364 -13% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014 2014 Q2
Q3 2012 $28,963 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2014 Q1
Q1 2012 $33,190 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013 2013 Q3
Q4 2011 $33,190 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013 2013 Q2

Perspective Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,221,000 +$2,078,000 +66% 01 Jan 2024 31 Dec 2024 10-K/A 28 Mar 2025 2024 FY
2023 $3,143,000 +$2,368,000 +306% 01 Jan 2023 31 Dec 2023 10-K/A 28 Mar 2025 2024 FY
2022 $775,000 +$389,000 +101% 01 Jul 2021 30 Jun 2022 10-K 28 Mar 2024 2023 FY
2021 $386,000 -$109,000 -22% 01 Jul 2020 30 Jun 2021 10-KT 01 May 2023 2023 Q1
2020 $495,000 +$75,000 +18% 01 Jul 2019 30 Jun 2020 10-KT 01 May 2023 2023 Q1
2019 $420,000 +$16,000 +4% 01 Jul 2018 30 Jun 2019 10-K 27 Sep 2021 2021 FY
2018 $404,000 +$32,000 +8.6% 01 Jul 2017 30 Jun 2018 10-K 25 Sep 2020 2020 FY
2017 $372,000 +$82,000 +28% 01 Jul 2016 30 Jun 2017 10-K 27 Sep 2019 2019 FY
2016 $290,000 +$85,000 +41% 01 Jul 2015 30 Jun 2016 10-K 26 Sep 2018 2018 FY
2015 $205,000 +$19,013 +10% 01 Jul 2014 30 Jun 2015 10-K 28 Sep 2017 2017 FY
2014 $185,987 +$77,636 +72% 01 Jul 2013 30 Jun 2014 10-K 09 Sep 2016 2016 FY
2013 $108,351 -$64,972 -37% 01 Jul 2012 30 Jun 2013 10-K 14 Sep 2015 2015 FY
2012 $173,323 01 Jul 2011 30 Jun 2012 10-K 30 Sep 2013 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.